Similar studies for GEO DataSets (Select 200094031) - GEO DataSets

Select item 2000940311.

Tamoxifen-associated endometrial tumors expose differential enhancer activity for Estrogen Receptor alpha [ChIP-Seq]

(Submitter supplied) Tamoxifen, a small molecule inhibitor that binds the Estrogen Receptor alpha (ERα), blocks breast cancer progression while increasing the risk for endometrial cancer. In this study, we assessed genome-wide ERα-chromatin interactions in surgical specimens of endometrial tumors from patients who were previously treated for breast cancer with tamoxifen, and endometrial tumors from patients who were treated without tamoxifen. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL11154
24 Samples

Download data: TXT

Series

Accession:: GSE94031

ID:: 200094031

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000945242.

Tamoxifen-associated endometrial tumors expose differential enhancer activity for Estrogen Receptor alpha

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL3676 GPL11154
135 Samples

Download data: TXT

Series

Accession:: GSE94524

ID:: 200094524

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000945233.

Tamoxifen-associated endometrial tumors expose differential enhancer activity for Estrogen Receptor alpha [Microarray Expression]

(Submitter supplied) Tamoxifen, a small molecule inhibitor that binds the Estrogen Receptor alpha (ERα), blocks breast cancer progression while increasing the risk for endometrial cancer. In this study, we assessed genome-wide ERα-chromatin interactions in surgical specimens of endometrial tumors from patients who were previously treated for breast cancer with tamoxifen, and endometrial tumors from patients who were treated without tamoxifen. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL3676
111 Samples

Download data: TXT

Series

Accession:: GSE94523

ID:: 200094523

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000812134.

Comparative cistromics reveals genomic crosstalk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas

(Submitter supplied) Tamoxifen, which is used to treat breast cancer, increases the risks of endometrial cancer. In this study, we performed a genome-wide assessment of ERα-chromatin interactions in surgical specimens obtained from patients with tamoxifen-associated endometrial cancer. ERα was found at active enhancers in endometrial cancer cells as marked by the presence of RNA polymerase II and the histone marker H3K27Ac. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL11154
23 Samples

Download data: TXT

Series

Accession:: GSE81213

ID:: 200081213

PubMed Similar studies SRA Run Selector

Select item 2000608825.

Effect of tamoxifen on early gene expression in T47D and MDA-MB-231 cells

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
6 Samples

Download data: CEL

Series

Accession:: GSE60882

ID:: 200060882

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000608796.

Effect of tamoxifen on early gene expression in MDA-MB-231 cells

(Submitter supplied) Tamoxifen is the treatment of choice in estrogen receptor alpha breast cancer patients. However, ~50% of ERα-positive tumors exhibit intrinsic or rapidly acquire resistance to endocrine treatment, requiring chemotherapy. Ιt has been difficult to predict de novo resistance to endocrine therapy and/or assess the likelihood of early relapse, while no concrete mechanism regulating the acquisition and the maintenance of endocrine resistance has been identified. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
3 Samples

Download data: CEL

Series

Accession:: GSE60879

ID:: 200060879

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000608787.

Effect of tamoxifen on early gene expression in T47D cells

(Submitter supplied) Tamoxifen is the treatment of choice in estrogen receptor alpha breast cancer patients. However, ~50% of ERα-positive tumors exhibit intrinsic or rapidly acquire resistance to endocrine treatment, requiring chemotherapy. Ιt has been difficult to predict de novo resistance to endocrine therapy and/or assess the likelihood of early relapse, while no concrete mechanism regulating the acquisition and the maintenance of endocrine resistance has been identified. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
3 Samples

Download data: CEL

Series

Accession:: GSE60878

ID:: 200060878

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000166808.

arrayCGH profiles of endometrial cancer with and without prior prolonged tamoxifen treatment for primary breast cancer

(Submitter supplied) Full title: comparison of the genomic (arrayCGH) profiles of endometrial cancer with and without prior prolonged tamoxifen treatment for primary breast cancer Purpose: Tamoxifen has been a very effective treatment for breast cancer for several decades, however, at the same time increases the risk of endometrial cancer, especially after prolonged exposure. In addition, tamoxifen has been associated with a higher proportion of unfavorable uterine tumor subtypes (carcinosarcomas and serous adenocarcinomas) with worse survival. more...

Organism:: Homo sapiens

Type:: Genome variation profiling by array

Platform:: GPL4560
97 Samples

Download data: TXT

Series

Accession:: GSE16680

ID:: 200016680

Select item 2000636079.

HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance

(Submitter supplied) Why breast cancers become resistant to tamoxifen despite continued expression of the estrogen receptor alpha (ERα) and what factors are responsible for high HER2 expression in these tumors remains an enigma. HOXB7 ChIP analysis followed by validation showed that HOXB7 physically interacts with ERα, and that the HOXB7-ERα complex enhances transcription of many ERα target genes including HER2. Investigating strategies for controlling HOXB7, our studies revealed that MYC, stabilized via phosphorylation mediated by EGFR-HER2 signaling, inhibits transcription of miRNA-196a, a HOXB7 repressor. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL10558
4 Samples

Download data: TXT

Series

Accession:: GSE63607

ID:: 200063607

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 20014464110.

An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERa action to confer to tamoxifen resistance in breast cancer

(Submitter supplied) Estrogen receptor alpha (ERalpha signaling pathway is essential for ERalpha positive breast cancer progression and endocrine therapy resistance. BPTF associated protein of 18kDa (BAP18) has been recognized as a crucial H3K4me3 reader. However, the whole genomic occupation of BAP18 and its biological function in breast cancer are still elusive. Here, we found that higher expression of BAP18 in ERalpha positive breast cancer is positively correlated with poor prognosis. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platform:: GPL16791
4 Samples

Download data: TXT

Series

Accession:: GSE144641

ID:: 200144641

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20000657711.

Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma

(Submitter supplied) Purpose: Endocrine therapies, such as tamoxifen are commonly given to most patients with estrogen receptor (ER) alpha-positive breast carcinoma but are not indicated for persons with ERalpha-negative cancer. The factors responsible for response to tamoxifen in 5-10% of patients with ERalpha-negative tumors are not clear. The aim of the present study was to elucidate the biology and role of the second ER, ERbeta, in patients treated with adjuvant tamoxifen. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS2827
Platform:: GPL3883
88 Samples

Download data: GPR

Series

Accession:: GSE6577

ID:: 200006577

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 282712.

ERalpha-negative ERbeta-positive breast carcinoma response to tamoxifen

Analysis of estrogen receptor (ER) alpha negative ERbeta-positive breast cancer tumors from patients treated with tamoxifen for 2 years. Unlike ERalpha-negative ERbeta-negative breast cancers, ERalpha-negative ERbeta-positive cancers respond favorably to tamoxifen treatment.

Organism:: Homo sapiens

Type:: Expression profiling by array, log2 ratio, 6 specimen sets

Platform:: GPL3883
Series:: GSE6577
88 Samples

Download data: GPR

DataSet

Accession:: GDS2827

ID:: 2827

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Select item 20010769313.

Comparing oestrogen-responsive genes in endometrial and breast cancer cell lines

(Submitter supplied) Up to 80% of endometrial and breast cancers express the oestrogen receptor ERa. Unlike breast cancer, anti-oestrogen therapy has had limited success in endometrial cancer, raising the possibility that oestrogen has different effects in the two cancer types. We investigated the role of oestrogen in endometrial and breast cancers using cell lines and found that oestrogen-responsive genes were predominantly unique between the two cancer types.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL18573
12 Samples

Download data: TXT

Series

Accession:: GSE107693

ID:: 200107693

Select item 20012444914.

A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor a-dependent transcriptional activation and breast carcinogenesis

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL16791 GPL21290
20 Samples

Download data: BIGWIG

Series

Accession:: GSE124449

ID:: 200124449

PubMed Full text in PMC Similar studies

Select item 20012444815.

A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor a-dependent transcriptional activation and breast carcinogenesis (ChIP-Seq)

(Submitter supplied) While protein arginine methyltransferases (PRMTs) and PRMT-catalyzed protein methylation have been well-known to be involved in a myriad of biological processes, their roles in carcinogenesis, particularly in estrogen receptor alpha (ERa)-positive breast cancers, remain incompletely understood. Here we focused on investigating PRMT4 (also called coactivator associated arginine methyltransferase 1, CARM1) due to its high expression and the associated poor prognosis in ERa-positive breast cancers. more...

Organism:: Homo sapiens

Type:: Genome binding/occupancy profiling by high throughput sequencing

Platforms:: GPL16791 GPL21290
6 Samples

Download data: BIGWIG

Series

Accession:: GSE124448

ID:: 200124448

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 20012444716.

A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor a-dependent transcriptional activation and breast carcinogenesis (RNA-seq)

(Submitter supplied) While protein arginine methyltransferases (PRMTs) and PRMT-catalyzed protein methylation have been well-known to be involved in a myriad of biological processes, their roles in carcinogenesis, particularly in estrogen receptor alpha (ERa)-positive breast cancers, remain incompletely understood. Here we focused on investigating PRMT4 (also called coactivator associated arginine methyltransferase 1, CARM1) due to its high expression and the associated poor prognosis in ERa-positive breast cancers. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL21290
14 Samples

Download data: BIGWIG

Series

Accession:: GSE124447

ID:: 200124447

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20010324317.

Tamoxifen Resistance in Breast Cancer is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL21290
16 Samples

Download data: TXT

Series

Accession:: GSE103243

ID:: 200103243

PubMed Full text in PMC Similar studies

Select item 20010324218.

The transcriptome effect of overexpressing EZH2 in MCF7

(Submitter supplied) Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in EZH2 overexpressed MCF-7 cells. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL21290
12 Samples

Download data: TXT

Series

Accession:: GSE103242

ID:: 200103242

PubMed Full text in PMC Similar studies Analyze with GEO2R SRA Run Selector

Select item 20009231619.

The transcriptome effect of knocking down EZH2 in TamR MCF7L

(Submitter supplied) Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in tamoxifen-resistant (TamR) MCF-7 cells. more...